Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Thomas Hengelage"'
Publikováno v:
Clinical Pharmacology & Therapeutics.
Autor:
Thomas Hengelage, Melissa Lynne Johnson, Daniel Shao-Weng Tan, Debbie Robbrecht, Helena Alexandra Yu, Kun Xu, Maria Jove, Geoffrey I. Shapiro, Irene Brana, Kelly Biette, Hironobu Minami, Lillian L. Siu, Eugene Tan, Neeltje Steeghs, Susan Moody
Publikováno v:
Journal of Clinical Oncology. 39:3005-3005
3005 Background: SHP2 transduces signals from activated receptor tyrosine kinases to downstream pathways including MAPK. TNO155 is a selective, allosteric, oral inhibitor of SHP2. Methods: CTNO155X2101 (NCT03114319) is an ongoing first-in-human, open
Autor:
Karl-Ludwig Schimz, Matthias Müller, Juan MacFarlane, Bernd Mechler, Christoph Neumann-Haefelin, Thomas Hengelage, Hedda K. Hoffschulte, Hans-Georg Koch
Publikováno v:
Molecular Biology of the Cell. 10:2163-2173
The molecular requirements for the translocation of secretory proteins across, and the integration of membrane proteins into, the plasma membrane of Escherichia coli were compared. This was achieved in a novel cell-free system from E. coliwhich, by e
Autor:
Hedda K. Hoffschulte, Thomas Hengelage, Hans-Georg Koch, Mathias Behrmann, Matthias Müller, Beate Wieseler
Publikováno v:
Journal of Biological Chemistry. 273:13898-13904
An oligodeoxynucleotide-dependent method to generate nascent polypeptide chains was adopted for use in a cell-free translation system prepared from Escherichia coli. In this way, NH2-terminal pOmpA fragments of distinct sizes were synthesized. Becaus
Autor:
Lihui Zhao, Natasha B. Leighl, Ronald Feld, Frances A. Shepherd, Thomas Hengelage, Lucien Gazi, Asha Nayak, Maria Grazia Porro, J. Thaddeus Beck, Margaret M. Woo
Publikováno v:
Cancer chemotherapy and pharmacology. 72(4)
Panobinostat is a potent oral pan-deacetylase inhibitor with promising clinical activity in hematologic malignancies. Panobinostat was shown to inhibit CYP2D6 activity in vitro; thus understanding the magnitude of the potential clinical inhibition of
Autor:
Geoffrey I. Shapiro, Lionel D. Lewis, Richard G. Frank, Lucien Gazi, Margaret M. Woo, Maria Grazia Porro, Lily Zhao, Thomas Hengelage, Uday B. Dandamudi
Panobinostat is a novel oral pan-deacetylase inhibitor with promising anti-cancer activity. The study aimed to determine the influence of food on the oral bioavailability of panobinostat.This multicenter study consisted of a randomized, three-way cro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df920c200edfd5125044c093aa261b09
https://europepmc.org/articles/PMC4491112/
https://europepmc.org/articles/PMC4491112/
Autor:
Paul Hamberg, Lin Chi Chen, Diane A.J. van der Biessen, Thomas Hengelage, Wenkui Li, Sunil Sharma, Lily Zhao, Jaap Verweij, Maja J.A. de Jonge, Margaret M. Woo, Maria Grazia Porro
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Panobinostat is partly metabolized by CYP3A4 in vitro. This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat. Methods Patients received a single panobinostat oral dose on
Autor:
Maria Grazia Porro, Jason Li, Nicole Hagner, Margaret M. Woo, Lucien Gazi, Hans Gelderblom, Annie St-Pierre, Dagmar Hess, Sally Clive, Thomas Hengelage, Neeraj Agarwal, Eva Rossmann, Sunil Sharma
Publikováno v:
Blood. 118:5007-5007
Abstract 5007 Panobinostat, an orally active hydroxamic acid derivative, is a potent class I/II/IV pan-deacetylase inhibitor that has shown promising clinical activity in hematologic and nonhematologic malignancies. Patients with cancer frequently ha
Autor:
Thomas Hengelage, Nicole Holtmeier, Anke Albrecht, Maike Krane, F. W. Falkenberg, Ina Bartels, Markus Wüthrich
Publikováno v:
Journal of immunological methods. 165(2)
This paper describes the construction and application of a low-cost roller bottle-like culture appliance in which hybridoma cells can be cultivated in high density in dialysis tubing. The appliance facilitates the simultaneous culture of up to four c
Autor:
Frances A. Shepherd, R. Elshtein, S. Hirawat, Thomas Hengelage, Ronald Feld, Natasha B. Leighl, Margaret M. Woo
Publikováno v:
Journal of Clinical Oncology. 28:e13089-e13089
e13089 Background: Panobinostat (PAN; LBH589) has been found to inhibit CYP2D6 in vitro. It was hypothesized that PAN may inhibit the metabolic clearance of comedications metabolized by CYP2D6 in p...